new warnings not to use high doses of IV ondansetron due to the risk of QT prolongation

September 2012

Please see updated FDA information (December 4, 2012) regarding the removal of 32 mg IV ondansetron products from the market.

You'll hear new warnings not to use high doses of IV ondansetron due to the risk of QT prolongation.

The max recommended single IV dose is now 16 mg instead of 32 mg.

This is similar to recent concerns about QT prolongation with higher doses of IV dolasetron (Anzemet). IV dolasetron is no longer approved for use for chemo-induced nausea and vomiting.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote